Clinical Trial Update: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating disitamab vedotin plus pembrolizumab versus chemotherapy in untreated HER2-expressing urothelial carcinoma; the study is active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Urothelial Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING